109 related articles for article (PubMed ID: 20197134)
1. Immunogenicity and some safety features of a VEGF-based cancer therapeutic vaccine in rats, rabbits and non-human primates.
Morera Y; Bequet-Romero M; Ayala M; Velazco JC; Pérez PP; Alba JS; Ancizar J; Rodríguez M; Cosme K; Gavilondo JV
Vaccine; 2010 Apr; 28(19):3453-61. PubMed ID: 20197134
[TBL] [Abstract][Full Text] [Related]
2. Antigen dose escalation study of a VEGF-based therapeutic cancer vaccine in non human primates.
Morera Y; Bequet-Romero M; Ayala M; Pérez PP; Castro J; Sánchez J; Alba JS; Ancízar J; Cosme K; Gavilondo JV
Vaccine; 2012 Jan; 30(2):368-77. PubMed ID: 22075086
[TBL] [Abstract][Full Text] [Related]
3. Experimental studies of a vaccine formulation of recombinant human VEGF antigen with aluminum phosphate.
Pérez Sánchez L; Morera Díaz Y; Bequet-Romero M; Ramses Hernández G; Rodríguez Y; Castro Velazco J; Puente Pérez P; Ayala Avila M; Gavilondo JV
Hum Vaccin Immunother; 2015; 11(8):2030-7. PubMed ID: 25891359
[TBL] [Abstract][Full Text] [Related]
4. CIGB-247: a VEGF-based therapeutic vaccine that reduces experimental and spontaneous lung metastasis of C57Bl/6 and BALB/c mouse tumors.
Bequet-Romero M; Morera Y; Ayala-Ávila M; Ancizar J; Soria Y; Blanco A; Suárez-Alba J; Gavilondo JV
Vaccine; 2012 Feb; 30(10):1790-9. PubMed ID: 22240345
[TBL] [Abstract][Full Text] [Related]
5. Anti-tumoral effect of active immunotherapy in C57BL/6 mice using a recombinant human VEGF protein as antigen and three chemically unrelated adjuvants.
Morera Y; Bequet-Romero M; Ayala M; Lamdán H; Agger EM; Andersen P; Gavilondo JV
Angiogenesis; 2008; 11(4):381-93. PubMed ID: 19034678
[TBL] [Abstract][Full Text] [Related]
6. Characteristics of the specific humoral response in patients with advanced solid tumors after active immunotherapy with a VEGF vaccine, at different antigen doses and using two distinct adjuvants.
Sánchez Ramírez J; Morera Díaz Y; Bequet-Romero M; Hernández-Bernal F; Selman-Housein Bernal KH; de la Torre Santos A; Santiesteban Álvarez ER; Martín Bauta Y; Bermúdez Badell CH; de la Torre Pupo J; Gavilondo JV; ; Ayala Avila M
BMC Immunol; 2017 Jul; 18(1):39. PubMed ID: 28747172
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of a xenogeneic VEGF vaccine in dogs with soft tissue sarcoma.
Kamstock D; Elmslie R; Thamm D; Dow S
Cancer Immunol Immunother; 2007 Aug; 56(8):1299-309. PubMed ID: 17502972
[TBL] [Abstract][Full Text] [Related]
8. Specific humoral response in cancer patients treated with a VEGF-specific active immunotherapy procedure within a compassionate use program.
Sánchez Ramírez J; Morera Díaz Y; Bequet-Romero M; Hernández-Bernal F; Martín Bauta Y; Selman-Housein Bernal KH; de la Torre Santos AV; Pérez de la Iglesia M; Trimiño Lorenzo L; ; Ayala Avila M
BMC Immunol; 2020 Mar; 21(1):12. PubMed ID: 32171254
[TBL] [Abstract][Full Text] [Related]
9. Specific humoral and cellular immune responses in cancer patients undergoing chronic immunization with a VEGF-based therapeutic vaccine.
Morera Y; Sánchez J; Bequet-Romero M; Selman-Housein KH; de la Torre A; Hernández-Bernal F; Martín Y; Garabito A; Piñero J; Bermúdez C; de la Torre J; Ayala M; Gavilondo JV
Vaccine; 2017 Jun; 35(28):3582-3590. PubMed ID: 28536029
[TBL] [Abstract][Full Text] [Related]
10. [Antitumor effect of recombinant T7 phage vaccine expressing xenogenic vascular endothelial growth factor on Lewis lung cancer in mice].
Li XH; Tang L; Liu D; Sun HM; Zhou CC; Tan LS; Wang LP; Zhang PD; Zhang SQ
Ai Zheng; 2006 Oct; 25(10):1221-6. PubMed ID: 17059764
[TBL] [Abstract][Full Text] [Related]
11. Generation of anti-idiotypic reagents in the EGFRvIII tumor-associated antigen system.
Wikstrand CJ; Cole VR; Crotty LE; Sampson JH; Bigner DD
Cancer Immunol Immunother; 2002 Feb; 50(12):639-52. PubMed ID: 11862416
[TBL] [Abstract][Full Text] [Related]
12. Priming and boosting determinants on the antibody response to an Epidermal Growth Factor-based cancer vaccine.
Rodriguez PC; Gonzalez I; Gonzalez A; Avellanet J; Lopez A; Perez R; Lage A; Montero E
Vaccine; 2008 Aug; 26(36):4647-54. PubMed ID: 18640164
[TBL] [Abstract][Full Text] [Related]
13. Specific active immunotherapy with a VEGF vaccine in patients with advanced solid tumors. results of the CENTAURO antigen dose escalation phase I clinical trial.
Gavilondo JV; Hernández-Bernal F; Ayala-Ávila M; de la Torre AV; de la Torre J; Morera-Díaz Y; Bequet-Romero M; Sánchez J; Valenzuela CM; Martín Y; Selman-Housein KH; Garabito A; Lazo OC;
Vaccine; 2014 Apr; 32(19):2241-50. PubMed ID: 24530151
[TBL] [Abstract][Full Text] [Related]
14. [Novel vaccines against M. tuberculosis].
Okada M
Kekkaku; 2006 Dec; 81(12):745-51. PubMed ID: 17240920
[TBL] [Abstract][Full Text] [Related]
15. Immunization with recombinant Brucella species outer membrane protein Omp16 or Omp19 in adjuvant induces specific CD4+ and CD8+ T cells as well as systemic and oral protection against Brucella abortus infection.
Pasquevich KA; Estein SM; García Samartino C; Zwerdling A; Coria LM; Barrionuevo P; Fossati CA; Giambartolomei GH; Cassataro J
Infect Immun; 2009 Jan; 77(1):436-45. PubMed ID: 18981242
[TBL] [Abstract][Full Text] [Related]
16. Active immunization with a detoxified endotoxin vaccine protects against lethal polymicrobial sepsis: its use with CpG adjuvant and potential mechanisms.
Opal SM; Palardy JE; Chen WH; Parejo NA; Bhattacharjee AK; Cross AS
J Infect Dis; 2005 Dec; 192(12):2074-80. PubMed ID: 16288370
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of tumor-induced myeloid-derived suppressor cell function by a nanoparticulated adjuvant.
Fernández A; Mesa C; Marigo I; Dolcetti L; Clavell M; Oliver L; Fernández LE; Bronte V
J Immunol; 2011 Jan; 186(1):264-74. PubMed ID: 21135171
[TBL] [Abstract][Full Text] [Related]
18. Prophylactic naked DNA vaccination with the human vascular endothelial growth factor induces an anti-tumor response in C57Bl/6 mice.
Bequet-Romero M; Ayala M; Acevedo BE; Rodríguez EG; Ocejo OL; Torrens I; Gavilondo JV
Angiogenesis; 2007; 10(1):23-34. PubMed ID: 17273909
[TBL] [Abstract][Full Text] [Related]
19. Innate-immunity cytokines induced by very small size proteoliposomes, a Neisseria-derived immunological adjuvant.
Venier C; Guthmann MD; Fernández LE; Fainboim L
Clin Exp Immunol; 2007 Feb; 147(2):379-88. PubMed ID: 17223981
[TBL] [Abstract][Full Text] [Related]
20. Complete antitumor protection by perioperative immunization with GM3/VSSP vaccine in a preclinical mouse melanoma model.
Gabri MR; Mazorra Z; Ripoll GV; Mesa C; Fernandez LE; Gomez DE; Alonso DF
Clin Cancer Res; 2006 Dec; 12(23):7092-8. PubMed ID: 17145833
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
